UXS1: a sweet spot for cell death

Gabrielle Brewer

DOI: https://doi.org/10.1038/s41568-023-00646-7

IF: 78.5

2023-12-01

Nature Reviews Cancer

Abstract:Enzymes that produce metabolites specifically required by cancer cells have become attractive targets for therapy. Recently, Doshi et al. highlighted the potential of targeting the detoxifying enzyme UXS1 in cancer.

oncology

What problem does this paper attempt to address?

UXS1 regulates UDP-GlcA levels to support growth of UGDH-high cancer cells

Yunyi Wang,Chen Zhou,Berna Bou-Tayeh,Richard Lisle,Skirmantas Kriaucionis,Yang Shi

DOI: https://doi.org/10.1101/2024.02.08.579288

2024-02-12

Abstract:Identifying genes that are crucial for cancer cell survival but dispensable in normal cells holds immense therapeutic potential. The DepMap Consortium’s extensive datasets have paved the way for uncovering such selectively essential genes in cancer. However, it remained challenging to efficiently prioritize understudied, selectively essential genes for validation and characterization. To this end, our lab has previously ranked and prioritized potentially understudied, selectively essential genes based on their PubMed publication numbers. This approach led to successful identification and detailed characterization of two top understudied genes. Building on this methodology, our current research identified UXS1, an enzyme responsible for catalyzing the conversion from UDP-glucuronic acid (UDP-GlcA) to UDP-xylose, as a selectively essential gene in cancer cells expressing elevated levels of UGDH, an enzyme responsible for producing UDP-GlcA. Through an integrated approach combining genetic and biochemical assays, we discovered that UXS1 plays a critical role in these UGDH-overexpressing cancer cells by preventing the harmful buildup of UDP-GlcA, which otherwise would lead to cellular toxicity. Our findings not only validate our strategy for prioritizing underexplored but potentially pivotal selectively essential genes but also highlight UXS1 as a potential vulnerability and therapeutic target in cancers characterized by high UGDH expression.

Cell Biology
UDP-glucose dehydrogenase (UGDH) in clinical oncology and cancer biology

Meghan J. Price,Annee D. Nguyen,Jovita K. Byemerwa,Jasmine Flowers,César D. Baëta,C. Rory Goodwin

DOI: https://doi.org/10.18632/oncotarget.28514

2023-09-28

Oncotarget

Abstract:UDP-glucose-6-dehydrogenase (UGDH) is a cytosolic, hexameric enzyme that converts UDP-glucose to UDP-glucuronic acid (UDP-GlcUA), a key reaction in hormone and xenobiotic metabolism and in the production of extracellular matrix precursors. In this review, we classify UGDH as a molecular indicator of tumor progression in multiple cancer types, describe its involvement in key canonical cancer signaling pathways, and identify methods to inhibit UGDH, its substrates, and its downstream products. As such, we position UGDH as an enzyme to be exploited as a potential prognostication marker in oncology and a therapeutic target in cancer biology.
USP29 coordinates MYC and HIF1α stabilization to promote tumor metabolism and progression

Rongfu Tu,Wenqian Kang,Mengjie Yang,Liyuan Wang,Qing Bao,Zhi Chen,Yang Dong,Jingchao Wang,Jue Jiang,Hudan Liu,Guoliang Qing

DOI: https://doi.org/10.1038/s41388-021-02031-w

IF: 8.756

2021-10-02

Oncogene

Abstract:Tumor cells must rewire cellular metabolism to satisfy the demands of unbridled growth and proliferation. How these metabolic processes are integrated to fuel cancer cell growth remains largely unknown. Deciphering the regulatory mechanisms is vital to develop targeted strategies for tumor-selective therapies. We herein performed an unbiased and functional siRNA screen against 96 deubiquitinases, which play indispensable roles in cancer and are emerging as therapeutic targets, and identified USP29 as a top candidate essential for metabolic reprogramming that support biosynthesis and survival in tumor cells. Integrated metabolic flux analysis and molecular investigation reveal that USP29 directly deubiquitinates and stabilizes MYC and HIF1α, two master regulators of metabolic reprogramming, enabling adaptive response of tumor cells in both normoxia and hypoxia. Systemic knockout of Usp29 depleted MYC and HIF1α in MYC-driven neuroblastoma and B cell lymphoma, inhibited critical metabolic targets and significantly prolonged survival of tumor-bearing mice. Strikingly, mice homozygous null for the Usp29 gene are viable, fertile, and display no gross phenotypic abnormalities. Altogether, these results demonstrate that USP29 selectively coordinates MYC and HIF1α to integrate metabolic processes critical for cancer cell growth, and therapeutic targeting of USP29, a potentially targetable enzyme, could create a unique vulnerability given deregulation of MYC and HIF1α frequently occurs in human cancers.

oncology,genetics & heredity,biochemistry & molecular biology,cell biology
Inhibition of Ubiquitin Specific Protease 1 Sensitizes Colorectal Cancer Cells to DNA-Damaging Chemotherapeutics.

Xin Xu,Shaoyan Li,Ximao Cui,Kunkun Han,Jun Wang,Xiaodan Hou,Long Cui,Songbing He,Jiecheng Xiao,Yili Yang

DOI: https://doi.org/10.3389/fonc.2019.01406

IF: 4.7

2019-01-01

Frontiers in Oncology

Abstract:Mutations and altered expression of deubiquitinating enzymes (DUBs) have been found associated with many human diseases including cancers. In this study, Ubiquitin specific protease 1 (USP1) expression was found significantly increased in some colorectal cancers (CRC). The elevated USP1 level was associated with short overall survival of patients and with advanced stages of cancers. In cultured CRC cells, knockdown of USP1 induced growth arrest at G(2)/M of cell cycle and reduced the expression of anti-apoptotic proteins Bcl-2 and Mcl-1. Its knockdown also led to reduction of DNA-repair related substrates FANCD2 and ID1. Further investigations found that small molecular inhibitor of USP1 ML323 sensitized CRC cells to DNA-targeting chemotherapeutics, including doxorubicin, TOPI/II inhibitors, and PARP inhibitor, but not to 5-Fu. These results indicate that USP1 plays a critical in colorectal cancer cell survival and is a promising target for anti-colorectal cancer chemotherapy. Targeting USP1 may represent an effective strategy to regulate the DNA-repairing system.
UCP2 and pancreatic cancer: conscious uncoupling for therapeutic effect

Caggiano, Emily G.,Taniguchi, Cullen M.

DOI: https://doi.org/10.1007/s10555-023-10157-4

2024-01-10

Cancer and Metastasis Reviews

Abstract:Pancreatic cancer has an exaggerated dependence on mitochondrial metabolism, but methods to specifically target the mitochondria without off target effects in normal tissues that rely on these organelles is a significant challenge. The mitochondrial uncoupling protein 2 (UCP2) has potential as a cancer-specific drug target, and thus, we will review the known biology of UCP2 and discuss its potential role in the pathobiology and future therapy of pancreatic cancer.

oncology
Xanthine dehydrogenase rewires metabolism and the survival of nutrient deprived lung adenocarcinoma cells by facilitating UPR and autophagic degradation

Man-man Chen,Wei Guo,Si-meng Chen,Xiao-zhen Guo,Lan Xu,Xiao-yu Ma,Yu-xiang Wang,Cen Xie,Ling-hua Meng

DOI: https://doi.org/10.7150/ijbs.78948

2023-01-01

International Journal of Biological Sciences

Abstract:Xanthine dehydrogenase (XDH) is the rate-limiting enzyme in purine catabolism by converting hypoxanthine to xanthine and xanthine to uric acid. The altered expression and activity of XDH are associated with the development and prognosis of multiple types of cancer, while its role in lung adenocarcinoma (LUAD) remains unknown. Herein, we demonstrated that XDH was highly expressed in LUAD and was significantly correlated with poor prognosis. Though inhibition of XDH displayed moderate effect on the viability of LUAD cells cultured in the complete medium, it significantly attenuated the survival of starved cells. Similar results were obtained in XDH-knockout cells. Nucleosides supplementation rescued the survival of starved LUAD cells upon XDH inhibition, while inhibition of purine nucleoside phosphorylase abrogated the process, indicating that nucleoside degradation is required for the XDH-mediated survival of LUAD cells. Accordingly, metabolic flux revealed that ribose derived from nucleoside fueled key carbon metabolic pathways to sustain the survival of starved LUAD cells. Mechanistically, down-regulation of XDH suppressed unfolded protein response (UPR) and autophagic flux in starved LUAD cells. Inhibition of XDH decreased the level of amino acids produced by autophagic degradation, which was accompanied with down-regulation of mTORC1 signaling. Supplementation of amino acids including glutamine or glutamate rescued the survival of starved LUAD cells upon knockout or inhibition of XDH. Finally, XDH inhibitors potentiated the anti-cancer activity of 2-deoxy-D-glucose that induced UPR and/or autophagy in vitro and in vivo. In summary, XDH plays a crucial role in the survival of starved LUAD cells and targeting XDH may improve the efficacy of drugs that induce UPR and autophagy in the therapy of LUAD.

biochemistry & molecular biology
Chemical Inductors of Proximity Associating DNA Damage-Binding Protein 2 and XIAP as Targeted Therapy for General Cancers

Leqi Shen

DOI: https://doi.org/10.56397/jimr/2023.10.09

2023-10-01

Abstract:While all cancers are classified as uncontrolled proliferations of cells, they manifest in many forms and may arise from a wide range of cellular anomalies. It has thus made finding a universal targeted cancer therapy a highly desirable goal. Several common biochemical changes associated with oncogenesis have been described in literature across all cancers, namely the Warburg effect (Heiden et al., 2009) (Warburg, 1925) and resistance to apoptosis (Hanahan & Weinburg, 2011). These hallmarks possess high potential to be used as targeting mechanisms in cancer treatment. Recent findings by Gourlsankar et al. have shown a promising new technique of linking the activity of a frequently activated cancer driver (B cell lymphoma 6) with an apoptosis promotor, allowing the creation of a synthetic biochemical pathway which rewires cancer driver activity to induce cell death, done through using a drug to covalently link two molecules that bond to each protein (Gourlsankar et al., 2023). While this approach specifically targeted diffuse large B cell lymphoma, it shows high promise for new strategies to approach eliminating cancer cells, namely in the artificial activation of tumor suppressor function through protein linkage and the consequent association in protein location within the cytosol. This paper aims to review the strategy of Gourlsankar et al., identifying ways to expand its concept towards generalized treatments using the hallmarks of cancer, and proposing a new theoretical drug mechanism using the linkage of DNA damage-binding protein 2 (DDB2) with X-linked inhibitor of apoptosis (XIAP) to induce cell death.
Deubiquitinating ALDH1A3 key to maintaining the culprit of aggressive brain cancer

Hiroaki Wakimoto

DOI: https://doi.org/10.1172/JCI128742

2019-04-08

Abstract:Cancer stem cells sustain propagation of the deadly primary brain cancer glioblastoma. Glioblastoma stem cells (GSCs) characterized by a mesenchymal phenotype are aggressive and resistant to therapies and represent a crucial therapeutic target. In this issue of the JCI, Chen et al. show that the intracellular levels of aldehyde dehydrogenase 1A3 (ALDH1A3), known as a functional marker of mesenchymal GSCs, are regulated posttranslationally by ubiquitin-specific protease 9X-mediated (USP9X-mediated) deubiquitination. Increased expression of USP9X stabilizes ALDH1A3, enabling GSCs to exhibit mesenchymal traits and the malignant phenotype. Thus, the USP9X-ALDH1A3 axis may offer a novel therapeutic target in glioblastoma.
Development and therapeutic potential of GSPT1 molecular glue degraders: A medicinal chemistry perspective

Xiujin Chang,Fangui Qu,Chunxiao Li,Jingtian Zhang,Yanqing Zhang,Yuanyuan Xie,Zhongpeng Fan,Jinlei Bian,Jubo Wang,Zhiyu Li,Xi Xu

DOI: https://doi.org/10.1002/med.22024

2024-02-06

Medicinal Research Reviews

Abstract:Unprecedented therapeutic targeting of previously undruggable proteins has now been achieved by molecular‐glue‐mediated proximity‐induced degradation. As a small GTPase, G1 to S phase transition 1 (GSPT1) interacts with eRF1, the translation termination factor, to facilitate the process of translation termination. Studied demonstrated that GSPT1 plays a vital role in the acute myeloid leukemia (AML) and MYC‐driven lung cancer. Thus, molecular glue (MG) degraders targeting GSPT1 is a novel and promising approach for treating AML and MYC‐driven cancers. In this Perspective, we briefly summarize the structural and functional aspects of GSPT1, highlighting the latest advances and challenges in MG degraders, as well as some representative patents. The structure‐activity relationships, mechanism of action and pharmacokinetic features of MG degraders are emphasized to provide a comprehensive compendium on the rational design of GSPT1 MG degraders. We hope to provide an updated overview, and design guide for strategies targeting GSPT1 for the treatment of cancer.

pharmacology & pharmacy,chemistry, medicinal
Targeting SUMOylation dependency in human cancer stem cells through a unique SAE2 motif revealed by chemical genomics

Yannick D Benoit,Ryan R Mitchell,Wenliang Wang,Luca Orlando,Allison L Boyd,Borko Tanasijevic,Lili Aslostovar,Zoya Shapovalova,Meaghan Doyle,Christopher J Bergin,Kinga Vojnits,Fanny L Casado,Justin Di Lu,Deanna P Porras,Juan Luis García-Rodriguez,Jennifer Russell,Aïcha Zouggar,Angelique N Masibag,Cody Caba,Kalinka Koteva,Lakshmana K Kinthada,Jagdish Suresh Patel,Sara N Andres,Jakob Magolan,Tony J Collins,Gerard D Wright,Mickie Bhatia,Yannick D. Benoit,Ryan R. Mitchell,Allison L. Boyd,Christopher J. Bergin,Fanny L. Casado,Deanna P. Porras,Angelique N. Masibag,Lakshmana K. Kinthada,Sara N. Andres,Tony J. Collins,Gerard D. Wright

DOI: https://doi.org/10.1016/j.chembiol.2021.04.014

IF: 9.039

2021-10-01

Cell Chemical Biology

Abstract:<h2 class="section-title u-h3 u-margin-l-top u-margin-xs-bottom">Summary</h2><p>Natural products (NPs) encompass a rich source of bioactive chemical entities. Here, we used human cancer stem cells (CSCs) in a chemical genomics campaign with NP chemical space to interrogate extracts from diverse strains of actinomycete for anti-cancer properties. We identified a compound (McM25044) capable of selectively inhibiting human CSC function versus normal stem cell counterparts. Biochemical and molecular studies revealed that McM025044 exerts inhibition on human CSCs through the small ubiquitin-like modifier (SUMO) cascade, found to be hyperactive in a variety of human cancers. McM025044 impedes the SUMOylation pathway via direct targeting of the SAE1/2 complex. Treatment of patient-derived CSCs resulted in reduced levels of SUMOylated proteins and suppression of progenitor and stem cell capacity measured <em>in vitro</em> and <em>in vivo</em>. Our study overcomes a barrier in chemically inhibiting oncogenic SUMOylation activity and uncovers a unique role for SAE2 in the biology of human cancers.</p>

biochemistry & molecular biology
Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors

Gabriel LaPlante,Wei Zhang

DOI: https://doi.org/10.3390/cancers13123079

2021-06-20

Cancers

Abstract:The ubiquitin-proteasome system (UPS) is a critical regulator of cellular protein levels and activity. It is, therefore, not surprising that its dysregulation is implicated in numerous human diseases, including many types of cancer. Moreover, since cancer cells exhibit increased rates of protein turnover, their heightened dependence on the UPS makes it an attractive target for inhibition via targeted therapeutics. Indeed, the clinical application of proteasome inhibitors in treatment of multiple myeloma has been very successful, stimulating the development of small-molecule inhibitors targeting other UPS components. On the other hand, while the discovery of potent and selective chemical compounds can be both challenging and time consuming, the area of targeted protein degradation through utilization of the UPS machinery has seen promising developments in recent years. The repertoire of proteolysis-targeting chimeras (PROTACs), which employ E3 ligases for the degradation of cancer-related proteins via the proteasome, continues to grow. In this review, we will provide a thorough overview of small-molecule UPS inhibitors and highlight advancements in the development of targeted protein degradation strategies for cancer therapeutics.

oncology
USP10 as a Potential Therapeutic Target in Human Cancers

Li Tao,Xiao Liu,Xinya Jiang,Kun Zhang,Yijing Wang,Xiumin Li,Shulong Jiang,Tao Han

DOI: https://doi.org/10.3390/genes13050831

IF: 4.141

2022-05-07

Genes

Abstract:Deubiquitination is a major form of post-translational protein modification involved in the regulation of protein homeostasis and various cellular processes. Deubiquitinating enzymes (DUBs), comprising about five subfamily members, are key players in deubiquitination. USP10 is a USP-family DUB featuring the classic USP domain, which performs deubiquitination. Emerging evidence has demonstrated that USP10 is a double-edged sword in human cancers. However, the precise molecular mechanisms underlying its different effects in tumorigenesis remain elusive. A possible reason is dependence on the cell context. In this review, we summarize the downstream substrates and upstream regulators of USP10 as well as its dual role as an oncogene and tumor suppressor in various human cancers. Furthermore, we summarize multiple pharmacological USP10 inhibitors, including small-molecule inhibitors, such as spautin-1, and traditional Chinese medicines. Taken together, the development of specific and efficient USP10 inhibitors based on USP10's oncogenic role and for different cancer types could be a promising therapeutic strategy.

genetics & heredity
Molecular Insights into the Recruiting Between UCP2 and DDX5/UBAP2L in the Metabolic Plasticity of Non-Small-Cell Lung Cancer

Zhiwei Yang,Guoyin Li,Yizhen Zhao,Lei Zhang,Xiaohui Yuan,Lingjie Meng,Huadong Liu,Yong Han,Lintao Jia,Shengli Zhang

DOI: https://doi.org/10.1021/acs.jcim.1c00138

IF: 6.162

2021-01-01

Journal of Chemical Information and Modeling

Abstract:Mitochondrial uncoupling protein 2 (UCP2) is distributed in tumor cells with a link to the support of systemic metabolic deregulation, and the downregulation of UCP2 has been unveiled as a biomarker of oncogenesis and chemoresistance in non-small-cell lung cancer (NSCLC) cells. However, the underlying mechanism of how UCP2 cooperates with other proteins in this metabolic reprogramming remains largely unsolved. We employed a combined computational and experimental strategy to explore into the recruiting of DDX5 with other proteins, and we unraveled the underlying structural mechanisms. We found that recruiting by ATP-dependent RNA helicase DDX5 (DDX5)/ubiquitin-associated protein 2-like (UBAP2L) might help UCP2 to play the pathological roles in NSCLC cells. According to the view of thermodynamics in physics, UCP2 tends to recruit DDX5 rather than UBAP2L, as shown by the ensemble-based docking, molecular dynamics simulations and molecular mechanics generalized Born surface area (MM/GBSA) approach. Cellular immunofluorescence assays further demonstrated that UCP2 associate with DDX5, and the recruiting of DDX5 with UCP2 at least partially contribute to the metabolic plasticity of NSCLCs via the AKT/mTOR pathway. Our study proposed an efficient way for detecting the protein- protein association via the experimentally validated molecular simulation. Our results shed light on the functional annotation of UCP and DDX family proteins in dysregulated metabolism, and the identification of candidate therapeutic targets for NSCLC.
Depleting DDX1 sensitizes non-small cell lung cancer cells to chemotherapy by attenuating cancer stem cell traits

Qi Yang,Pei Xu,Qingtao Liu,Fengqing Hu,Xiao Xie,Lianyong Jiang,Rui Bi,Lei Wang,Fangbao Ding,Haibo Xiao

DOI: https://doi.org/10.1016/j.lfs.2023.121592

2023-06-15

Abstract:Aims: DEAD-box helicase 1 (DDX1) has oncogenic properties in several human cancers. However, the clinical significance and biological role of DDX1 in non-small cell lung cancer (NSCLC) remain elusive. Here, we examined the chemotherapeutic relevance of DDX1 in NSCLC. Main methods: We used the UALCAN database, Western blot analysis, and immunohistochemical and RT-qPCR assays to assess DDX1 expression in NSCLC cell lines (H1650 and A549) and patient tissues. The role of DDX1 in the chemosensitivity of NSCLC cells and the underlying mechanisms were determined using colony formation, CCK-8, flow cytometry, wound healing, Transwell, tumor sphere formation, and immunostaining assays, together with a xenograft tumor model in nude mice. Key findings: Our study revealed that DDX1 was overexpressed in NSCLC cell lines and tissues. We further found that depleting DDX1 increased the sensitivity of NSCLC cells to the chemotherapy drug cisplatin, increased cell apoptosis, and inhibited cell migration and invasion. Co-immunoprecipitation assays revealed that DDX1 bound to ADAR1, and increased ADAR1 protein expression. Furthermore, we found that ADAR1 mediated cancer-promoting effects, independent of deaminase activity, by binding to RAC3 mRNA. Our findings not only show that DDX1 mediates chemosensitivity to cisplatin via the ADAR1/RAC3 axis but also highlight the importance of ADARs as essential RNA-binding proteins for cell homeostasis, as well as cancer progression. Significance: Our results suggest that DDX1 plays an important role in the development and progression of human NSCLC and that DDX1 may serve as a therapeutic target in NSCLC patients.
Cellular functions, molecular signalings and therapeutic applications: Translational potential of deubiquitylating enzyme USP9X as a drug target in cancer treatment

Hongli Gao,Zhiguang Chen,Liang Zhao,Ce Ji,Fei Xing

DOI: https://doi.org/10.1016/j.bbcan.2024.189099

Abstract:Protein ubiquitination, one of the most significant post-translational modifications, plays an important role in controlling the proteins activity in diverse cellular processes. The reversible process of protein ubiquitination, known as deubiquitination, has emerged as a critical mechanism for maintaining cellular homeostasis. The deubiquitinases (DUBs), which participate in deubiquitination process are increasingly recognized as potential candidates for drug discovery. Among these DUBs, ubiquitin-specific protease 9× (USP9X), a highly conserved member of the USP family, exhibits versatile functions in various cellular processes, including the regulation of cell cycle, protein endocytosis, apoptosis, cell polarity, immunological microenvironment, and stem cell characteristics. The dysregulation and abnormal activities of USP9X are influenced by intricate cellular signaling pathway crosstalk and upstream non-coding RNAs. The complex expression patterns and controversial clinical significance of USP9X in cancers suggest its potential as a prognostic biomarker. Furthermore, USP9X inhibitors has shown promising antitumor activity and holds the potential to overcome therapeutic resistance in preclinical models. However, a comprehensive summary of the role and molecular functions of USP9X in cancer progression is currently lacking. In this review, we provide a comprehensive delineation of USP9X participation in numerous critical cellular processes, complicated signaling pathways within the tumor microenvironment, and its potential translational applications to combat therapeutic resistance. By systematically summarizing the updated molecular mechanisms of USP9X in cancer biology, this review aims to contribute to the advancement of cancer therapeutics and provide essential insights for specialists and clinicians in the development of improved cancer treatment strategies.
USP32 confers cancer cell resistance to YM155 via promoting ER-associated degradation of solute carrier protein SLC35F2

Arun Pandian Chandrasekaran,Kamini Kaushal,Chang-Hwan Park,Kye-Seong Kim,Suresh Ramakrishna

DOI: https://doi.org/10.7150/thno.63806

IF: 11.6

2021-01-01

Theranostics

Abstract:Background: The most commonly preferred chemotherapeutic agents to treat cancers are small-molecule drugs. However, the differential sensitivity of various cancer cells to small molecules and untargeted delivery narrow the range of potential therapeutic applications. The mechanisms responsible for drug resistance in a variety of cancer cells are also largely unknown. Several deubiquitinating enzymes (DUBs) are the main determinants of drug resistance in cancer cells. Methods: We used CRISPR-Cas9 to perform genome-scale knockout of the entire set of genes encoding ubiquitin-specific proteases (USPs) and systematically screened for DUBs resistant to the clinically evaluated anticancer compound YM155. A series of in vitro and in vivo experiments were conducted to reveal the relationship between USP32 and SLC35F2 on YM155-mediated DNA damage in cancer cells. Results: CRISPR-based dual-screening method identified USP32 as a novel DUB that governs resistance for uptake of YM155 by destabilizing protein levels of SLC35F2, a solute-carrier protein essential for the uptake of YM155. The expression of USP32 and SLC35F2 was negatively correlated across a panel of tested cancer cell lines. YM155-resistant cancer cells in particular exhibited elevated expression of USP32 and low expression of SLC35F2. Conclusion: Collectively, our DUB-screening strategy revealed a resistance mechanism governed by USP32 associated with YM155 resistance in breast cancers, one that presents an attractive molecular target for anti-cancer therapies. Targeted genome knockout verified that USP32 is the main determinant of SLC35F2 protein stability in vitro and in vivo, suggesting a novel way to treat tumors resistant to small-molecule drugs.

medicine, research & experimental
MUC1 oncoprotein mitigates ER stress via CDA-mediated reprogramming of pyrimidine metabolism

Appolinaire A. Olou,Ryan J. King,Fang Yu,Pankaj K. Singh

DOI: https://doi.org/10.1038/s41388-020-1225-4

IF: 8.756

2020-02-26

Oncogene

Abstract:The Mucin 1 (MUC1) protein is overexpressed in various cancers and mediates chemotherapy resistance. However, the mechanism is not fully understood. Given that most chemotherapeutic drugs disrupt ER homeostasis as part of their toxicity, and MUC1 expression is regulated by proteins involved in ER homeostasis, we investigated the link between MUC1 and ER homeostasis. MUC1 knockdown in pancreatic cancer cells enhanced unfolded protein response (UPR) signaling and cell death upon ER stress induction. Transcriptomic analysis revealed alterations in the pyrimidine metabolic pathway and cytidine deaminase (CDA). ChIP and CDA activity assays showed that MUC1 occupied CDA gene promoter upon ER stress induction correlating with increased CDA expression and activity in MUC1-expressing cells as compared with MUC1 knockdown cells. Inhibition of either the CDA or pyrimidine metabolic pathway diminished survival in MUC1-expressing cancer cells upon ER stress induction. Metabolomic analysis demonstrated that MUC1-mediated CDA activity corresponded to deoxycytidine to deoxyuridine metabolic reprogramming upon ER stress induction. The resulting increase in deoxyuridine mitigated ER stress-induced cytotoxicity. In addition, given (1) the established roles of MUC1 in protecting cells against reactive oxygen species (ROS) insults, (2) ER stress-generated ROS further promote ER stress and (3) the emerging anti-oxidant property of deoxyuridine, we further investigated if MUC1 regulated ER stress by a deoxyuridine-mediated modulation of ROS levels. We observed that deoxyuridine could abrogate ROS-induced ER stress to promote cancer cell survival. Taken together, our findings demonstrate a novel MUC1-CDA axis of the adaptive UPR that provides survival advantage upon ER stress induction.

oncology,genetics & heredity,biochemistry & molecular biology,cell biology
Disulfidptosis decoded: a journey through cell death mysteries, regulatory networks, disease paradigms and future directions

Jinyu Chen,Boyuan Ma,Yubiao Yang,Bitao Wang,Jian Hao,Xianhu Zhou

DOI: https://doi.org/10.1186/s40364-024-00593-x

2024-04-29

Biomarker Research

Abstract:Abstract Cell death is an important part of the life cycle, serving as a foundation for both the orderly development and the maintenance of physiological equilibrium within organisms. This process is fundamental, as it eliminates senescent, impaired, or aberrant cells while also promoting tissue regeneration and immunological responses. A novel paradigm of programmed cell death, known as disulfidptosis, has recently emerged in the scientific circle. Disulfidptosis is defined as the accumulation of cystine by cancer cells with high expression of the solute carrier family 7 member 11 (SLC7A11) during glucose starvation. This accumulation causes extensive disulfide linkages between F-actins, resulting in their contraction and subsequent detachment from the cellular membrane, triggering cellular death. The RAC1-WRC axis is involved in this phenomenon. Disulfidptosis sparked growing interest due to its potential applications in a variety of pathologies, particularly oncology, neurodegenerative disorders, and metabolic anomalies. Nonetheless, the complexities of its regulatory pathways remain elusive, and its precise molecular targets have yet to be definitively identified. This manuscript aims to meticulously dissect the historical evolution, molecular underpinnings, regulatory frameworks, and potential implications of disulfidptosis in various disease contexts, illuminating its promise as a groundbreaking therapeutic pathway and target.

oncology,medicine, research & experimental
Tumor integrin-targeted glucose oxidase enzyme promotes ROS-mediated cell death that combines with interferon alpha therapy for tumor control

Jordan A. Stinson,Allison Sheen,Brianna M. Lax,Grace N. Yang,Lauren Duhamel,Luciano Santollani,Elizabeth Fink,Joseph Palmeri,K. Dane Wittrup

DOI: https://doi.org/10.1158/1535-7163.mct-24-0163

2024-10-11

Molecular Cancer Therapeutics

Abstract:While heightened intratumoral levels of reactive oxygen species (ROS) are typically associated with a suppressive tumor microenvironment, under certain conditions ROS contribute to tumor elimination. Treatment approaches, including some chemotherapy and radiation protocols, increase cancer cell ROS levels that influence their mechanism of cell death and subsequent recognition by the immune system. Furthermore, activated myeloid cells rapidly generate ROS upon encounter with pathogens or infected cells to eliminate disease, and recently, this effector function has been noted in cancer contexts as well. Collectively, ROS-induced cancer cell death may help initiate adaptive anti-tumor immune responses that could synergize with current approved immunotherapies, for improved control of solid tumors. In this work, we explore the use of glucose oxidase, an enzyme which produces hydrogen peroxide, a type of ROS, to therapeutically mimic the endogenous oxidative burst from myeloid cells to promote antigen generation within the tumor microenvironment. We engineer the enzyme to target pan-tumor expressed integrins both as a tumor-agnostic therapeutic approach, but also as a strategy to prolong local enzyme activity following intratumoral administration. We found the targeted enzyme potently induced cancer cell death and enhanced cross-presentation by dendritic cells in vitro, and further combined with interferon alpha for long-term tumor control in murine MC38 tumors in vivo. Optimizing the single-dose administration of this enzyme overcomes limitations with immunogenicity noted for other pro-oxidant enzyme approaches. Overall, our results suggest ROS-induced cell death can be harnessed for tumor control, and highlight the potential use of designed enzyme therapies alongside immunotherapy against cancer.

oncology
The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is topoisomerase II poisoning

Mengrou Lu,Haider Inam,John Sheehe,Peter M. Bruno,Kady A. Dennis,Connor J. Moore,Stephen J. Elledge,Michael T. Hemann,Justin R. Pritchard

DOI: https://doi.org/10.1073/pnas.1921649117

IF: 11.1

2020-02-10

Proceedings of the National Academy of Sciences

Abstract:Significance Small molecules can directly and indirectly interfere with multiple cellular processes simultaneously. However, there is a difference between what a molecule can do and what mechanisms cause cellular cytotoxicity. Genetic logic using CRISPR works well when discriminating between essential and nonessential target hypotheses. However, discriminating between competing hypotheses across multiple essential pathways is more challenging. Here we combine three complementary data-driven approaches to create multimodal measurements of the mechanism of cytotoxicity. Our multimodal data mining approach coupled to genetic, cell biologic, and biochemical experiments allowed us to detangle essential processes and reannotate CX-5461 as a topoisomerase II poison. Correct annotation is critical for charting a clinical development path and effectively using CX-5461 as a chemical genetic probe.

multidisciplinary sciences

UXS1: a sweet spot for cell death

UXS1 regulates UDP-GlcA levels to support growth of UGDH-high cancer cells

UDP-glucose dehydrogenase (UGDH) in clinical oncology and cancer biology

USP29 coordinates MYC and HIF1α stabilization to promote tumor metabolism and progression

Inhibition of Ubiquitin Specific Protease 1 Sensitizes Colorectal Cancer Cells to DNA-Damaging Chemotherapeutics.

UCP2 and pancreatic cancer: conscious uncoupling for therapeutic effect

Xanthine dehydrogenase rewires metabolism and the survival of nutrient deprived lung adenocarcinoma cells by facilitating UPR and autophagic degradation

Chemical Inductors of Proximity Associating DNA Damage-Binding Protein 2 and XIAP as Targeted Therapy for General Cancers

Deubiquitinating ALDH1A3 key to maintaining the culprit of aggressive brain cancer

Development and therapeutic potential of GSPT1 molecular glue degraders: A medicinal chemistry perspective

Targeting SUMOylation dependency in human cancer stem cells through a unique SAE2 motif revealed by chemical genomics

Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors

USP10 as a Potential Therapeutic Target in Human Cancers

Molecular Insights into the Recruiting Between UCP2 and DDX5/UBAP2L in the Metabolic Plasticity of Non-Small-Cell Lung Cancer

Depleting DDX1 sensitizes non-small cell lung cancer cells to chemotherapy by attenuating cancer stem cell traits

Cellular functions, molecular signalings and therapeutic applications: Translational potential of deubiquitylating enzyme USP9X as a drug target in cancer treatment

USP32 confers cancer cell resistance to YM155 via promoting ER-associated degradation of solute carrier protein SLC35F2

MUC1 oncoprotein mitigates ER stress via CDA-mediated reprogramming of pyrimidine metabolism

Disulfidptosis decoded: a journey through cell death mysteries, regulatory networks, disease paradigms and future directions

Tumor integrin-targeted glucose oxidase enzyme promotes ROS-mediated cell death that combines with interferon alpha therapy for tumor control

The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is topoisomerase II poisoning